featured
De Novo vs Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From the SystHERs Registry
Oncologist 2020 Feb 01;25(2)e214-e222, D Tripathy, A Brufsky, M Cobleigh, M Jahanzeb, PA Kaufman, G Mason, J O'Shaughnessy, HS Rugo, SM Swain, DA Yardley, L Chu, H Li, V Antao, SA HurvitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.